BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/25/2022 7:27:40 AM | Browse: 606 | Download: 1265
 |
Received |
|
2021-03-25 09:04 |
|
Peer-Review Started |
|
2021-03-25 09:07 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-07-27 06:30 |
|
Revised |
|
2021-08-11 21:33 |
|
Second Decision |
|
2022-01-11 03:44 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-01-11 19:54 |
|
Articles in Press |
|
2022-01-11 19:54 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2022-01-07 17:18 |
|
Typeset the Manuscript |
|
2022-01-19 16:23 |
|
Publish the Manuscript Online |
|
2022-01-25 07:27 |
| ISSN |
2220-3192 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Pharmacology & Pharmacy |
| Manuscript Type |
Editorial |
| Article Title |
Mammalian target of rapamycin; novel insight for management of inflammatory bowel diseases
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Naser-Aldin Lashgari, Nazanin Momeni Roudsari, Saeideh Momtaz and Amir Hossein Abdolghaffari |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Amir Hossein Abdolghaffari, PhD, Assistant Professor, Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, No. 99, Yakhchal, Gholhak, Shariati St., Tehran 1941933111, Iran. amirhosein172@hotmail.com |
| Key Words |
Inflammatory bowel diseases; Inflammation; Mammalian target of rapamycin; Mammalian target of rapamycin inhibitors |
| Core Tip |
Inflammation is the main participant in inflammatory bowel diseases (IBD) pathogenesis and development. Since the mammalian target of rapamycin (mTOR) pathways are suggested to be involved in IBD progression, inhibition of the mTOR signaling may lead to a novel treatment modality for patients with IBD. Several biologics, synthetic and natural compounds were introduced as mTOR inhibitors, which may be favorable, preferably in clinical state, to either control or eradicate the intestinal inflammatory conditions such as IBD. |
| Publish Date |
2022-01-25 07:27 |
| Citation |
Lashgari NA, Roudsari NM, Momtaz S, Abdolghaffari AH. Mammalian target of rapamycin; novel insight for management of inflammatory bowel diseases. World J Pharmacol 2022; 11(1): 1-5 |
| URL |
https://www.wjgnet.com/2220-3192/full/v11/i1/1.htm |
| DOI |
https://dx.doi.org/10.5497/wjp.v11.i1.1 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
